Health-care utilization and costs with fluticasone propionate and fluticasone propionate/salmeterol in asthma patients at risk for exacerbations

Hagiwara M, Delea TE, Stanford RH

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details
Hagiwara M, Delea TE, Stanford RH. Health-care utilization and costs with fluticasone propionate and fluticasone propionate/salmeterol in asthma patients at risk for exacerbations. Allergy and Asthma Proceedings 2014; 35(1): 54-62

PubMedID
24433597

DOI
10.2500/aap.2014.35.3720

Indexing Status
Subject indexing assigned by NLM

MeSH
Adolescent; Adrenergic beta-2 Receptor Agonists /administration & dosage /economics /therapeutic use; Albuterol /administration & dosage /analogs & derivatives /economics /therapeutic use; Androstadienes /administration & dosage /economics /therapeutic use; Anti-Allergic Agents /administration & dosage /economics /therapeutic use; Asthma /drug therapy /economics; Drug Therapy, Combination; Female; Fluticasone; Health Care Costs; Humans; Male; Patient Compliance; Retrospective Studies; Salmeterol Xinafoate; Treatment Outcome; Young Adult

AccessionNumber
22014010032

Date bibliographic record published
29/04/2014